Drugs / FOLR1 CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06609928 | Feb 2025 → Oct 2027 expected | childhood acute myeloid leukemia | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOLR1 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06609928 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.” NCT06609928 ↗ |
| Route | Intravenous | “Given IV” NCT06609928 ↗ |